Skip to main content

Table 2 Carcinoma-related treatment in 253 patients with breast carcinoma and diabetes (128 receiving and 125 not receiving metformin) and 320 patients with breast carcinoma without diabetes

From: Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Factor Sub-group Patients with breast carcinoma and diabetes without metformin (N = 125) Patients with breast carcinoma and diabetes on metformin (N = 128) Patients with breast carcinoma without diabetes (N = 320) P1 P2
Breast surgical procedure Quadrantectomy or lumpectomy 48 59 157 0.21 0.13
Mastectomy 77 69 163   
Axillary surgical procedure Sentinel node biopsy 54 61 147 0.43 0.73
Lymphadenectomy 71 67 173
Adjuvant chemotherapy No 94 87 196 0.20 0.02
Yes 31 41 124
Adjuvant hormone therapy No 14 15 76 0.89 0.0001
Yes 111 113 244
Adjuvant trastuzumab No 118 115 285 0.17 0.22
Yes 7 13 35
Adjuvant radiotherapy No 60 52 135 0.23 0.44
Yes 65 76 185
  1. P1: p-value (DM not on metformin vs. DM on metformin).
  2. P2: p-value (DM not on metformin vs. DM on metformin vs. controls).